HC Wainwright reaffirmed their buy rating on shares of Veru (NASDAQ:VERU - Free Report) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $3.00 price target on the stock.
Separately, Oppenheimer reiterated an "outperform" rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th.
Get Our Latest Analysis on Veru
Veru Stock Up 0.2 %
Shares of NASDAQ:VERU traded up $0.00 during midday trading on Thursday, reaching $0.65. The company's stock had a trading volume of 1,898,766 shares, compared to its average volume of 1,613,038. The firm has a market capitalization of $95.41 million, a PE ratio of -1.36 and a beta of -0.50. The stock has a fifty day moving average of $0.70 and a 200 day moving average of $0.80. Veru has a twelve month low of $0.36 and a twelve month high of $1.92.
Veru (NASDAQ:VERU - Get Free Report) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. Sell-side analysts anticipate that Veru will post -0.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Veru
A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC raised its position in Veru by 26.5% in the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company's stock valued at $5,942,000 after purchasing an additional 1,478,578 shares during the period. Geode Capital Management LLC grew its stake in shares of Veru by 4.7% in the third quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company's stock valued at $2,261,000 after buying an additional 131,720 shares in the last quarter. State Street Corp raised its holdings in shares of Veru by 4.3% in the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company's stock valued at $1,593,000 after buying an additional 84,483 shares during the period. PVG Asset Management Corp lifted its stake in Veru by 13.1% during the 3rd quarter. PVG Asset Management Corp now owns 636,970 shares of the company's stock worth $490,000 after acquiring an additional 73,815 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Veru by 1,718.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company's stock valued at $373,000 after acquiring an additional 419,374 shares during the period. 47.16% of the stock is currently owned by institutional investors and hedge funds.
About Veru
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
